Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBPP) EBT Margin (2016 - 2025)

Historic EBT Margin for Regen BioPharma (RGBPP) over the last 11 years, with Q3 2025 value amounting to 964.3%.

  • Regen BioPharma's EBT Margin fell 5082400.0% to 964.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 538.76%, marking a year-over-year decrease of 2562700.0%. This contributed to the annual value of 538.76% for FY2025, which is 2562700.0% down from last year.
  • Regen BioPharma's EBT Margin amounted to 964.3% in Q3 2025, which was down 5082400.0% from 283.23% recorded in Q2 2025.
  • Over the past 5 years, Regen BioPharma's EBT Margin peaked at 32.77% during Q1 2025, and registered a low of 964.3% during Q3 2025.
  • For the 5-year period, Regen BioPharma's EBT Margin averaged around 309.91%, with its median value being 216.5% (2022).
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 5693600bps in 2023, then tumbled by -6271900bps in 2024.
  • Quarter analysis of 5 years shows Regen BioPharma's EBT Margin stood at 239.45% in 2021, then crashed by -240bps to 814.74% in 2022, then skyrocketed by 70bps to 245.38% in 2023, then crashed by -256bps to 872.57% in 2024, then decreased by -11bps to 964.3% in 2025.
  • Its EBT Margin was 964.3% in Q3 2025, compared to 283.23% in Q2 2025 and 32.77% in Q1 2025.